{"name":"Azienda Ospedaliera San Giovanni Battista","slug":"azienda-ospedaliera-san-giovanni-battista","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fludarabin","genericName":"Fludarabin","slug":"fludarabin","indication":"Acute myeloid leukemia, disease","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"lysine acetylsalicylate","genericName":"lysine acetylsalicylate","slug":"lysine-acetylsalicylate","indication":"Acute pain and fever","status":"marketed"}]}],"pipeline":[{"name":"Fludarabin","genericName":"Fludarabin","slug":"fludarabin","phase":"marketed","mechanism":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","indications":["Acute myeloid leukemia, disease","Chronic lymphoid leukemia, disease","Low-grade B cell non-Hodgkin lymphoma","Mantle cell lymphoma"],"catalyst":""},{"name":"lysine acetylsalicylate","genericName":"lysine acetylsalicylate","slug":"lysine-acetylsalicylate","phase":"marketed","mechanism":"Lysine acetylsalicylate is a salt form of aspirin that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide analgesic, anti-inflammatory, and antiplatelet effects.","indications":["Acute pain and fever","Cardiovascular protection and antiplatelet therapy","Inflammatory conditions"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}